Atomoxetine improves orthostatic blood pressure in neurogenic orthostatic hypotension
Atomoxetine improved orthostatic blood pressure in patients with neurogenic orthostatic hypotension (nOH) and was found to safe and effective, according to a study.
In this prospective open-label randomized trial, 50 patients with nOH received with atomoxetine 18 mg daily or midodrine 5 mg twice daily. After 1 month, patients who still met the criteria for nOH received midodrine and atomoxetine for an additional 2 months.
After 1 month, only 26.2% of the patients overall continued to have nOH. Patients in both groups showed comparative improvement in the orthostatic blood pressure drop, although only patients treated with atomoxetine experienced significant symptomatic improvements.
Combination treatment did not improve symptoms in patients whose nOH remained after 1 month,
Byun JI, Kim DY, Moon J, et al. Efficacy of atomoxetine versus midodrine for neurogenic orthostatic hypotension [published correction appears in Ann Clin Transl Neurol. 2020 Mar;7(3):402]. Ann Clin Transl Neurol. 2020;7(1):112-120. doi:10.1002/acn3.50968